Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Do you offer IV iron first line to women with iron deficiency anemia from heavy menstrual bleeding?

1
1 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

I offer first-line IV iron because oral iron cannot keep up with the losses from heavy menstrual bleeding, and the majority can't tolerate it. I routinely give a gram of LMW iron dextran in one hour, Feraheme (not ferumoxytol generic) 1,020 mg in 30 minutes, or ferric derisomaltose 1 gram in 30 minu...

Is there greater efficacy of TPO-RA in patients who have undergone a splenectomy?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Wisconsin

In the pivotal clinical trials of romiplostim and eltrombopag, there was no strong relationship between splenectomy status and treatment response. In my experience, however, some splenectomized patients exhibit dramatic, rapid increases in the platelet count when treated with a TPO-RA drug, presumab...

Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of California Davis Comprehensive Cancer Center

I typically do not give enasidenib with azacitidine upfront for patients with AML with IDH2 mutation and ineligible for intensive induction chemotherapy. Based on the results of the VIALE-A study (DiNardo et al, NEJM 2020), I usually give venetoclax with azacitidine to those patients. In addition to...

Does the lack of long-term data influence your consideration of utilizing zanubrutinib and venetoclax 1L in High-Risk CLL?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Kansas Cancer Center

Not really. The CLL17 data showed essentially equivalent 3yr PFS between ibrutinib + venetoclax, ibrutinib monotherapy, and venetoclax + obinutuzumab. But even before those data were published, with the solid 36-month PFS data for zanubrutinib + venetoclax, it seemed clear that many of these patient...

Are there any alternative, hypofractionated RT courses for patients with DLBCL that can be used during the COVID-19 pandemic?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · David Geffen School of Medicine at UCLA

ILROG recently came out with guidelines pasted below: Synopsis of ILROG Recommendations for Administering Radiotherapy for Hematological Malignancies During Emergency Conditions of the COVID-19 Pandemic • We are facing an increased demand for RT to substitute or complement systemic therapy deemed i...

What is your approach to screening a cancer survivor for iron overload, and what is your treatment of choice?

1
2 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Phoenix Childrens Medical Group

We check the ferritin level after completion of chemotherapy. If ferritin is >1,000 ng/ml, we recheck the level as it can be falsely elevated with inflammation/infection. If ferritin is >1,000, we obtain a liver MRI with iron quantification. If liver iron concentration (LIC) is > 5 mg/g dry weight, ...

Do you repeat images in patients with venous thrombosis to inform decision about duration of anticoagulation?

2
2 Answers

Mednet Member
Mednet Member
Hematology · Gundersen Health

The short answer is "no". I do reimage many people near the end of the 3-6 months of treatment, but it doesn't really change my mind about duration of treatment in most instances. I use repeat imaging to help me understand how much of the clot resolved and thus, determine what their new baseline is....

How long do you anticoagulate for cirrhosis patients who have portal vein thrombosis extending to the mesenteric veins?

1
2 Answers

Mednet Member
Mednet Member
Hematology · University of Alabama at Birmingham

I recommend indefinite anticoagulation for most patients with portal vein thrombosis, and at least 3-6 months if there are risk factors for bleeding. Once they complete anticoagulation for the first 6 months, I re-evaluate their risk of recurrent thrombosis vs bleeding, and if there is an underlying...

How do you approach managing depression symptoms in patients who have had repeated high risk of bleeding?

6
2 Answers

Mednet Member
Mednet Member
Psychiatry · University of Colorado

Overall, evidence suggests that while SSRIs do increase the risk of bleeding. The absolute risk of a bleeding event remains low and is usually not serious. A 2017 meta-analysis by Laporte et al., suggested that overall bleeding risk is increased by at least 36% while other meta-analyses suggest that...

Would you use argatroban or citrate catheter lock in a patient with ESKD and HITT?

2
3 Answers

Mednet Member
Mednet Member
Nephrology · UnMCNephrology Division

I would use 4% citrate. I have no experience using argatroban as a catheter lock solution, but have significant experience using 4% citrate solution. For our inpatients, we only use 4% citrate solution (and have done so for many years). While I believe you can buy prefilled 4% citrate syringes comme...